Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

With the business potentially at an important milestone, we thought we'd take a closer look at ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) future prospects. ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The US$1.0b market-cap company posted a loss in its most recent financial year of US$54m and a latest trailing-twelve-month loss of US$49m shrinking the gap between loss and breakeven. The most pressing concern for investors is ARS Pharmaceuticals' path to profitability – when will it breakeven? Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for ARS Pharmaceuticals

ARS Pharmaceuticals is bordering on breakeven, according to the 4 American Biotechs analysts. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$5.8m in 2026. So, the company is predicted to breakeven approximately 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 71%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving ARS Pharmaceuticals' growth isn’t the focus of this broad overview, however, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing we’d like to point out is that ARS Pharmaceuticals has no debt on its balance sheet, which is rare for a loss-making biotech, which typically has high debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of ARS Pharmaceuticals which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at ARS Pharmaceuticals, take a look at ARS Pharmaceuticals' company page on Simply Wall St. We've also put together a list of pertinent aspects you should further examine:

1. Valuation: What is ARS Pharmaceuticals worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether ARS Pharmaceuticals is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on ARS Pharmaceuticals’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.